Extracellular region of epidermal growth factor receptor: a potential target for anti-EGFR drug discovery

The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer

(2016) F. J. Sanchez-Martin et al.   CLINICAL CANCER RESEARCH

MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations

(2016) Sabrina Arena et al.   Science Translational Medicine

Second-line panitumumab as a triweekly dose for patients with wild-type KRAS exon 2 metastatic colorectal cancer: a single-institution experience

(2016) Mohamed A. Daoud et al.   Cancer Biology & Medicine

Acquired resistance to anti-EGFR mAb ICR62 in cancer cells is accompanied by an increased EGFR expression, HER-2/HER-3 signalling and sensitivity to pan HER blockers

(2015) Said A Khelwatty et al.   BRITISH JOURNAL OF CANCER

Enhanced dimerization drives ligand-independent activity of mutant epidermal growth factor receptor in lung cancer

(2015) Christopher C. Valley et al.   MOLECULAR BIOLOGY OF THE CELL

Mechanisms of resistance to EGFR tyrosine kinase inhibitors

(2015) Lihua Huang et al.   Acta Pharmaceutica Sinica B

Gefitinib resistance resulted from STAT3-mediated Akt activation in lung cancer cells

(2015) Kai Wu et al.   Oncotarget

Expression of EGFRvIII in Glioblastoma: Prognostic Significance Revisited

(2015) Nicola Montano et al.   NEOPLASIA

Oncogenic KRAS signalling in pancreatic cancer

(2014) S Eser et al.   BRITISH JOURNAL OF CANCER

Targeting the Fc receptor in autoimmune disease

(2014) Xinrui Li et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Epidermal growth factor receptor (EGFR) exon 20 mutations in non-small-cell lung cancer and resistance to EGFR-tyrosine kinase inhibitors

(2014) Hyun Sun Woo et al.   INVESTIGATIONAL NEW DRUGS

CRKL amplification is rare as a mechanism for acquired resistance to kinase inhibitors in lung cancers with epidermal growth factor receptor mutation

(2014) Kenichi Suda et al.   LUNG CANCER

PIK3CA Mutations Frequently Coexist with EGFR/KRAS Mutations in Non-Small Cell Lung Cancer and Suggest Poor Prognosis in EGFR/KRAS Wildtype Subgroup

(2014) Lei Wang et al.   PLoS One

AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer

(2014) D. A. E. Cross et al.   Cancer Discovery

EGFR wild type antagonizes EGFRvIII-mediated activation of Met in glioblastoma

(2013) L Li et al.   ONCOGENE

EGF receptor trafficking: consequences for signaling and cancer

(2013) Alejandra Tomas et al.   TRENDS IN CELL BIOLOGY

Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer

(2013) Nir Peled et al.   CELLULAR ONCOLOGY

Homeostasis and the Importance for a Balance Between AKT/mTOR Activity and Intracellular Signaling

(2012) D. A. Altomare et al.   CURRENT MEDICINAL CHEMISTRY

Targeting the EGFR signaling pathway in cancer therapy

(2012) Parthasarathy Seshacharyulu et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Activation of IL-6R/JAK1/STAT3 Signaling Induces De Novo Resistance to Irreversible EGFR Inhibitors in Non-Small Cell Lung Cancer with T790M Resistance Mutation

(2012) S. M. Kim et al.   MOLECULAR CANCER THERAPEUTICS

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer

(2012) Zhenfeng Zhang et al.   NATURE GENETICS

Modeling of Tumor Progression in NSCLC and Intrinsic Resistance to TKI in Loss of PTEN Expression

(2012) Gholamreza Bidkhori et al.   PLoS One

Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab

(2011) Toni M. Brand et al.   CANCER BIOLOGY & THERAPY

Targeting antibodies to the cytoplasm

(2011) Andrea L.J. Marschall et al.   mAbs

EGFRvIII promotes glioma angiogenesis and growth through the NF-κB, interleukin-8 pathway

(2011) R Bonavia et al.   ONCOGENE

Understanding resistance to EGFR inhibitors—impact on future treatment strategies

(2010) Deric L. Wheeler et al.   Nature Reviews Clinical Oncology

TGF-  IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer

(2010) Z. Yao et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFR

(2009) M. L. Sos et al.   CANCER RESEARCH

Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy

(2009) E. Martinelli et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors

(2009) A F Gazdar   ONCOGENE

The epidermal growth factor receptor family: Biology driving targeted therapeutics

(2008) M. J. Wieduwilt et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

(2008) C.-H. Yun et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA